Jacobson Pharma Reports Interim Results with Increased Shareholder Dividends
I'm PortAI, I can summarize articles.
Jacobson Pharma Corporation Limited reported a 5.4% revenue decrease to HK$766.6 million for the six months ending 30 September 2025. Despite this, profit attributable to shareholders rose by 1.2% to HK$142.0 million. The Board declared an interim dividend of HK4.25 cents per share, a 21.4% increase from the previous year. The stock is rated Hold with a HK$1.50 price target. Jacobson Pharma focuses on generic drugs and proprietary medicines, listed on the Hong Kong Stock Exchange under code 2633.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments